CDK7-IN-17

• UNSPSC Description:

  CDK7-IN-17 is a potent inhibitor of CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1)[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk7-in-17.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [H][C@]12C[C@@H](C[C@]1(C[C@@H](C2)N)[H])NC3=NC=C(C(C4=CNC5=C(C(C#N)=CC=C45)P(C)(C)=O)=N3)C(F)(F)F

• Molecular Weight:

  502.47

• References & Citations:

  [1]Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2765676-60-4